Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 1/20 | 0.39 |
| ▸ | TACR1 | P25103 | 8/20 | 0.38 |
| ▸ | TACR2 | P21452 | 5/20 | 0.38 |
| ▸ | CCR5 | P51681 | 4/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3019414 | 0.84 | TACR1 (0.39) | RORCTACR1TACR2CCR5CNR2 | |
| SCHEMBL3032339 | 0.81 | TACR1 (0.40) | RORCTACR1TACR2CCR5SIGMAR1 | |
| SCHEMBL3032336 | 0.81 | TACR1 (0.40) | RORCTACR1TACR2CCR5SIGMAR1 | |
| SCHEMBL3025622 | 0.80 | ALDH1A1 (0.43) | RORCTACR1TACR2CCR5SIGMAR1 | |
| SCHEMBL3031891 | 0.80 | HIF1A (0.43) | RORCTACR1TACR2CCR5SIGMAR1 | |
| SCHEMBL28030186 | 0.80 | RORC (0.45) | RORCCCR5SIGMAR1DPP4CNR2 | |
| SCHEMBL28030659 | 0.79 | CCR5 (0.42) | RORCTACR1TACR2CCR5SIGMAR1 | |
| SCHEMBL3029620 | 0.78 | CCR5 (0.44) | RORCTACR1TACR2CCR5SIGMAR1 | |
| SCHEMBL3029997 | 0.78 | CCR5 (0.44) | RORCTACR1TACR2CCR5SIGMAR1 | |
| SCHEMBL2779465 | 0.78 | SLC6A2 (0.35) | CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2398768-B1 | PYRROLIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2016-08-24 | — | — | EP | disclosed |
| US-8318759-B2 | Pyrrolidine derivatives as NK3 receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2012-11-27 | — | — | US | disclosed |
| US-20100210659-A1 | PYRROLIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | HOFFMANN-LA ROCHE, INC. | 2010-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210659-A1 | PYRROLIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | OPRL1, OPRK1, OPRD1 | RORC 1018/4885TACR1 7/4885TACR2 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.